B. Braun continues to grow in a demanding environment

“We are pleased with development in the 2024 fiscal year,” said Anna Maria Braun, Chief Executive Officer of B. Braun SE, at a virtual press conference today. “The sales growth is a clear indicator that our products and solutions are convincing. Thanks to our clear focus and discipline, we have achieved a good improvement in result.​ This is a strong performance by all employees, enabling us to continue investing in modern technologies for better health care.”

At constant exchange rates, B. Braun recorded an increase in sales of 6.8 percent in the 2024 fiscal year. The company continued its long-term growth within its strategic target corridor of 5 to 7 percent. Sales rose by 4.4 percent to 9.1 billion euros (previous year: 8.8 billion euros) in the Group's currency.

B. Braun successfully improved its efficiency in the 2024 fiscal year. The gross margin increased by 1.3 percentage points to 39.2 percent of sales
(previous year: 37.9 percent). This was largely accomplished with optimization in production and growth in profitable segments. This made it possible to offset higher energy and raw materials procurement costs, higher personnel expenses and unscheduled depreciation.   

EBITDA reached 1,101.9 million euros (previous year: 1,019.4 million euros), while the EBITDA margin improved by 0.5 percentage points to 12.1 percent of sales (previous year: 11.6 percent of sales). Profit before taxes increased by 31.1 percent at 270.0 million euros (previous year: 206.0 million euros).

Thanks to the improved earnings situation, B. Braun was able to continue investing in 2024: a total of 1.3 billion euros was spent on new technologies, research and development, and the expansion of production capacities. The company invested 5.8 percent of its sales revenues in research and development in the 2024 fiscal year. Over the next few years, B. Braun intends to increase this figure to over 6 percent, in order to strengthen its position as a leading medical technology company.

Innovations for better health care

B. Braun continued to drive innovations in 2024 to improve internal processes and workflows for its customers. By combining products, software and services, the company is creating smart solutions that become a critical part of the treatments its customers provide. The Space^plus infusion pump system and OnlineSuite^plus offer all the benefits of modern connectivity and data management. These include standardized interfaces, cloud-based applications, device management and update flexibility, as well as enhanced convenience. The Space^plus system improves safety, efficiency and patient orientation, and supports clinics on the road to digitalization.

In the 2024 fiscal year, B. Braun also developed an innovative solution for intensive care units with other medical device manufacturers. Devices from various providers are connected, to enable central device alerts and visualization of bedside activity, and to reduce noise levels. This improves workflows for health care staff and promotes patient health by creating a quieter environment.

Sterile goods management from B. Braun represents the core of integrated solutions that make resource and supply processes more efficient and increase productivity and safety in the operating room. Smart products and services ensure that health care professionals have the right surgical instruments at the right time, without having to worry about delays or missing equipment. This means the surgical team can concentrate more on the operation, which creates the best conditions for a positive treatment outcome. The sterile container system also produces 95 percent less waste when compared to disposable packaging material, saving a medium-sized clinic with approximately 10,000 operations a year over 3.1 tons of waste annually. 

B. Braun is also focusing on efficiency and digital technologies in the continuous development of its dialysis portfolio. For example, the OMNI dialysis machine has been supplemented by an innovative virtual reality training program specifically developed for medical staff working in intensive care units. This VR training enables critical situations to be practiced realistically without blocking the use of a dialysis machine. The VR glasses also allow for flexible and location-independent learning, which is particularly valuable in times of staff shortages.

Number of employees increased in selected areas

The number of employees at the B. Braun Group increased to 64,262 in 2024 (previous year: 63,011). The new employees were primarily hired for production and research and development. Thanks to the different perspectives, backgrounds and experiences of its employees, B. Braun can continuously innovate and set new standards in health care. “Products and solutions from B. Braun were used in 194 countries in 2024. The diversity of our workforce is essential for us to successfully develop and market our portfolio worldwide,” said Anna Maria Braun. “I would like to thank every employee for their commitment, ability to change and flexibility in the past fiscal year. These characteristics enable us to serve as a true partner for our customers, and to further advance health care with modern technologies.”

Further information on the business development of B. Braun SE can be found in the current Annual Report at www.bbraun.com/annual-report

Further information on current B. Braun topics:

• How B. Braun makes data usable for medicine:
  www.bbraun.com/smart-data-usage
• How B. Braun saves time for medical professionals:
  www.bbraun.com/healthcare-challenges
• How B. Braun creates a healthier intensive care environment: 
  Silent ICU: Ensuring seamless medical device interoperability
• How B. Braun creates innovations with agile research and development:
  www.bbraun.com/agile-development
• How B. Braun takes responsibility for patients:
  www.bbraun.com/we-care